Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Jim Momtazee
AddedMar 31, 2024
UpdatedMay 31, 2026
Jim Momtazee

Jim Momtazee

Board Member, Roivant Sciences

LinkedIn

Jim Momtazee's Career

Roivant Sciences
Roivant Sciences

New York City, NY, US

Board Member· Board
BridgeBio Pharma
BridgeBio Pharma

Palo Alto, CA, US

Board Member· Board
Kriya Therapeutics
Kriya Therapeutics

Palo Alto, CA, US

Board Member· Board
Syneos Health
Syneos Health

Morrisville, NC, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Jim Momtazee's Career

Roivant Sciences
Roivant Sciences
Public$2.5B2672014New York City, NY, US
Board Member· Board

Leadership at Roivant Sciences

Atul PandeAtul PandeBoard Member
Lanny SunLanny SunCo-Founder
Andrew LoAndrew LoBoard Member
Ilan Ben OrenIlan Ben OrenBoard Member
Matthew GlineMatthew GlineCEO
George MigauskyGeorge MigauskyBoard Member
BridgeBio Pharma
BridgeBio Pharma
Public$3.6B3922015Palo Alto, CA, US
Board Member· Board

Leadership at BridgeBio Pharma

Charles HomcyCharles HomcyBoard Member
Richard SchellerRichard SchellerBoard Member
Jennifer CookJennifer CookBoard Member
Neil KumarNeil KumarFounder
Andrea EllisAndrea EllisBoard Member
Randy ScottRandy ScottBoard Member
Kriya Therapeutics
Kriya Therapeutics
Series C$600.5M1942019Palo Alto, CA, US
Board Member· Board

Leadership at Kriya Therapeutics

Roger JeffsRoger JeffsBoard Member
Shankar RamaswamyShankar RamaswamyCo-Founder
Fraser WrightFraser WrightCo-Founder

Similar to Kriya Therapeutics

Krystal BiotechKrystal BiotechPittsburgh, PA, USGene Therapyest. 2017Krystal BiotechPittsburgh, PA, US · est. 2017

Krystal Biotech: A Pennsylvania-based biopharmaceutical firm pioneering gene therapy for rare disorders.

Public · $546M210
Voyager TherapeuticsVoyager TherapeuticsCambridge, MA, USGene Therapyest. 2014Voyager TherapeuticsCambridge, MA, US · est. 2014

Cambridge-based Voyager Therapeutics, Inc. is a clinical-stage gene therapy company developing treatments for severe CNS diseases.

Public · $374M125
NephrogenNephrogenNew York City, NY, USGene Therapiesest. 2020NephrogenNew York City, NY, US · est. 2020

Nephrogen: Crafting gene cures for kidney diseases, focusing on PKD.

Seed · $150k1
Kate TherapeuticsKate TherapeuticsSan Diego, CA, USGene TherapyKate TherapeuticsSan Diego, CA, US

KateTx, a gene therapy biotech firm, focuses on developing AAV-based therapies for genetic muscle and heart diseases.

Series A · $51M44
Syneos Health
Syneos Health
Public$999.6M29.4k1998Morrisville, NC, US
Board Member· Board

Leadership at Syneos Health

John DineenJohn DineenBoard Member
Paul MeisterPaul MeisterBoard Member
Colin ShannonColin ShannonBoard Member
Linda HartyLinda HartyBoard Member
Michael BellMichael BellBoard Member
Alfonso ZuluetaAlfonso ZuluetaBoard Member

Similar to Syneos Health

QuintilesQuintilesDurham, NC, USDrug Developmentest. 1982QuintilesDurham, NC, US · est. 1982

Quintiles: Outsourcing biopharmaceutical development and commercial services for innovative therapies.

Public · $3.5B10k
SyapseSyapseSan Francisco, CA, USReal-World Evidenceest. 2008SyapseSan Francisco, CA, US · est. 2008

Syapse: Advancing real-world care to alleviate serious disease burden with evidence-based solutions.

Public · $222.6M147
IQVIAIQVIADurham, NC, USHealthcare Dataest. 1954IQVIADurham, NC, US · est. 1954

Healthcare technology company in Danbury, CT.

Public · $1.5B87k
MedpaceMedpaceCincinnati, OH, USClinical Researchest. 1992MedpaceCincinnati, OH, US · est. 1992

Medpace, a global clinical research organization, accelerates the development of safe, effective medical therapeutics.

Public5.2k

Jim Momtazee's Similar Executives & Operators

Jay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoYun SeokYun SeokBoard Member · Kakao

People Similar to Jim Momtazee

Michael BeindorffMichael BeindorffBoard Member · LifeVantageRobert DelvesRobert DelvesBoard Member · Proximity SpaceAlex MootAlex MootCo-Founder · Blue Highway CapitalDan MillerDan MillerBoard Member · Cornell UniversityBrian KushnerBrian KushnerBoard Member · Cumulus MediaThomas MalleyThomas MalleyBoard Member · BeOne Medicines